Introduction {#Sec1}
============

Cardiovascular diseases (CVD) are the major causes of morbidity and mortality in type 2 diabetes \[[@CR1]\], which death rate accounts for 75% \[[@CR2]\]. It is widely accepted that lipid metabolism, Body Mass Index (BMI), waist circumference (WC), Homeostasis model assessment (HOMA), High-Sensitivity C-reactive protein (Hs-CRP) and carotid intima-media thickness (IMT) are dominant risk factors of cardiovascular disease (CVD) \[[@CR3]--[@CR5]\]. If not adequately controlled, these risk factors would increase CVD events, and they are also significant for clinical.

In prospective epidemiologic studies, the incidence of microvascular complications is directly linked with the degree of hyperglycemia, represented by the glycosylated hemoglobin level(HbA1c), which is expressed as mean blood glucose level during the previous 2 to 3 months \[[@CR6]\]. Meanwhile, UKPDS shows that an increase of 1% in HbA1c is associated with an increase of 37% in the risk of retinopathy or kidney disease \[[@CR7]\]. However, ACCORD and ADVANCE have failed to provide an additional benefit in CVD with long-standing diabetes \[[@CR8]--[@CR10]\], even after maintaining near-normal HbA1c level in persons with type 2 diabetes. As a corollary, the uncertainty around HbA1c results related to clinical outcomes was augmented. Meanwhile, these findings suggest that near-normal HbA1c does not possibly improve CVD outcomes, so it's incompleteness need to fill out. Glucose variability(GV) mainly refer to as time in range and is unacceptable in hypo- and hyperglycemic range (\<70 and 180 mg/dL, respectively) \[[@CR11]\], it has emerged as a key unmet need.

Although GV is emerging as an important dynamic parameter of diabetes control, its clinical importance is not fully characterized. Growing studies have reignited the emphasis that GV is a risk factor for diabetic complication. In general, much studies of GV in vitro laboratory evidence show that GV could increase production of reactive oxygen species and has a detrimental effect on endothelial dysfunction, even CVD \[[@CR12]\]. While similar findings have also been shown in clinical studies \[[@CR13]\], others have been unable to confirm any association \[[@CR14]\]. Understanding mechanism of GV to CVD may help unravel some of the mystery about mac-complication in type 2 diabetes. So we aimed to describe association between CVD risk factor levels and GV in type 2 diabetes, providing opportunities for early diagnosis and targets for novel treatments.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

This review was performed by the Preferred Reporting Items for Systematic reviews and Meta Analyses guideline \[[@CR15]\]. We searched PubMed, EMBASE, Cochrane Library, Web of science, Wan Fang Data and CNKI from 1970 to October 12, 2016 by using text words (diabetes \[Title/Abstract\]) AND (randomized clinical trial) AND (glucose variability OR glycemic variability OR glucose fluctuation OR glucose instability OR glycemic fluctuation). All relevant abstracts were obtained from our search. References from these studies were reviewed for additional citations and all potential articles.

Trial eligibility and selection {#Sec4}
-------------------------------

We included Chinese and English-language, full paper, randomized controlled clinical trials (RCTs) conducted in adult over 18 years of age patients with type 2 diabetes. The search strategy mainly focus on the association between GV and major CVD risk factors with type 2 diabetes, which include BMI \[[@CR4]\], WC, TC, TG, HDL, LDL \[[@CR3]\], Hs-CRP \[[@CR5]\], HOMA and IMT. Studies that captured at least two group of glucose variability, including Mean blood glucose (MBG), coefficient of variation (CV), standard deviation(SD), mean amplitude of glycemic excursions (MAGE), mean of daily differences (MODD), continuous overall net glycemic action(CONGA), standard deviation-glycosylated hemoglobin (SD-HbA1c), and standard deviation-Fasting plasma glucose (SD-FPG) \[[@CR12], [@CR16]\], assessed using either self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) or reported a measure of GV were included in the review, and that were excluded if they had an impaired peripheral arterial disease, renal, liver, coronary heart disease, and stroke on the baseline. By contacting the corresponding authors, attempt to acquire studies that did not report the required data on GV and CVD risk factors.

Quality and characteristics of included studies were assessed regarding the methodological characteristics, statistical analysis, characteristics of the outcome by two reviewers. Where there was disagreement over the eligibility of a study, the article was discussion together and a consensus was reached.

Data analysis and synthesis {#Sec5}
---------------------------

Because there are no generally accepted gold standard for assessing GV and little consensus for most accurate assessment of GV \[[@CR16]\], and each has its own advantages and disadvantages, and it is no consistent assessment index of GV in all studies, therefore GV level are divided into two groups to ensure comprehensive. Comparable studies in terms of GV levels were pooled for meta-analysis if they were statistically significant between experimental group and control group, we define that low amplitude of GV was low glucose variability group (LGVG) and high amplitude of GV is high glucose variability group (HGVG).

In this meta-analysis, mean difference (MD) and standardized mean difference (SMD) were applied all the meta-analysis. Random effects models were used to consider study variation. I^2^ index is to estimate heterogeneity, namely used to determine whether differences exist between studies \[[@CR17]\]. Heterogeneity is low if I2 \< 30%, heterogeneity is moderate if I^2^ is 30% -- 50%, and heterogeneity is concluded if *P* \< 0.10 and I^2^ \> 50% \[[@CR17]\]. Analyses were undertaken using Review Manager 5.3.

Bias assessment {#Sec6}
---------------

Bias, being caused by literature search and data analysis, can lead to under- or over-estimation of the true intervention effects in clinical trials. In this meta-analysis, publication bias was assessed using Egger's test \[[@CR18]\]. Sensitivity analyses were assessed by removing one study at a time on the pooled estimate.

Note: Body Mass Index (BMI), waist circumference (WC), Total Cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), C-reactive protein (CRP), Homeostasis model assessment (HOMA) and Length of Inner Metatarsal Tubercle (IMT).

Results {#Sec7}
=======

Among these studies, four authors were contacted for missing data, but no authors provided additional information, so 22 studies are included for full-text review in the meta-analysis, representing a total sample of 1143 patients in HGVG and 1275 patients in LGVG, 1183 studies are removed based on our inclusion and exclusion criteria (Fig. [1](#Fig1){ref-type="fig"}), and the vast majority studies were excluded as reviews or not reporting either a measure of GV or no the associated CVD risk factors of interest. These eligible studies contained data on two different groups. And the studies characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Sensitivity analyses revealed that no particular study affected significantly the summary effects for CVD risk factors. Findings from Egger's test supported the finding that except LDL, others were no publication bias (Table [2](#Tab2){ref-type="table"}). When one article was excluded, the publication bias of LDL is non-existent (P: 0.328).Fig. 1Flow diagram for identifying eligible studies Table 1Characteristics of included studiesStudy,YearSample Size (n)(high GV /low GV)Glucose variability indiceFollow up (month)Age (mean/arrange)Men (%)EthnicsCVD risk factorsPanwei Mu 2011 \[[@CR31]\]126/124CV-FBG34042.8XanthousTC,TG,HDL,LDL,HOMA-IR,HOMA-βH.J. Yoo 2008 \[[@CR32]\]28/29MAGE320--8042.1XanthousTC,TG,HDL,LDL,BMI,WCSu Guirong 2014 \[[@CR33]\]28/27MBG SDBG MODD MAGE125052XanthousTC,TG,HDL,LDL,BMI,HOMA-IRShi Dou Lin 2011 \[[@CR34]\]20/20MBG SD MODD CONGA630--7057.5XanthousBMI,TC,TG,HDL,LDLGuoyue Yuan 2015 \[[@CR35]\]104/108CV MAGE0.54967.00XanthousBMI,TC,TG,HDL,LDL,Hs-CRP,HOMA-IRWeiping Sun 2016 \[[@CR36]\]52/51SD-HbA1c MAGE630--7052.78XanthousTC,TG,LDL,HDL,HOMA-IR,HOMA-βHunSung Kim 2013 \[[@CR37]\]17/16MBG SD MAGE218--8057.58XanthousTC,TG,HDL,LDLClaudia De Natale 2009 \[[@CR38]\]13/5CV MAGE15966.67CaucasianTC,TG,LDL,HDLJae-Hyoung Cho 2006 \[[@CR39]\]40/40SD-HbA1c30≥3061.25XanthousTC,TG,HDLYu Qian Bao 2010 \[[@CR19]\]20/20MBG MODD MAGE234--7041.3XanthousTC,TG,HDL,LDL,BMI,WC,HOMA-IR,HOMA-βHelene von Bibra 2016 \[[@CR40]\]48/61SD-HbA1c MAGE3635--8570.6CaucasianTC,TG,HDL,LDL,Hs-CRP,IMTJohn B Buse 2016 \[[@CR41]\]159/307MAGE1360.457.5CaucasianTG,HDL,LDLTomoya Mita 2016 \[[@CR42]\]152/151SD-HbA1c SD-FBG6≥3058.36XanthousIMT,TC, LDL, HDLJeannie Tay 2015 \[[@CR43]\]47/46MBG SD MAGE MODD CONGA-1 CONGA-4635--6867.74CaucasianWC,HOMA-IR,HOMA-β,Hs-CRP,TC,TG,HDL,LDLJeannie Tay 2015 \[[@CR44]\]37/41MAGE SD CONGA-1 CONGA-41335--6857.39CaucasianTC,TG,HDL,LDL,Hs-CRP,HOMA-IR,HOMA-βHeng Wan 2016 \[[@CR45]\]30/30SD MBG MAGE830--7046.5XanthousBMI,TC,TG,HDL,LDLHuang Zhanqiang 2012 \[[@CR46]\]40/40CV-FPG SDBG3≥6066.25XanthousTC,TG,HDL,LDLQiang Zhou 2008 \[[@CR47]\]56/50MAGE620--7562XanthousBMI, WCYanzhen Ye 2014 \[[@CR48]\]22/28MAGE SD184660.72XanthousTC,TG,HDL,LDLRuiting He 2016 \[[@CR49]\]60/60MBG MAGE SD LAGE105650XanthousBMI,TC,TG,LDL,HDLShuijing Zhou 2012 \[[@CR20]\]23/10MAGE2420--7050.94XanthousBMI,TG,TC,HDL,LDL,IMTWang Ruiping 2015 \[[@CR50]\]29/27MAGE160--8058.93XanthousTC,TG,WCNote: Body Mass Index (BMI), waist circumference (WC), Total Cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), C-reactive protein (CRP), Homeostasis model assessment (HOMA) and Length of Inner Metatarsal Tubercle (IMT) Table 2Summary of publication bias with Eggers testEgger testt (95%Cl)*P* BMIchange−0.17\[4.48,-4.85\]0.88final value0.1\[2.61,-2.39\]0.92 WCfinal value1.51\[−2.98,8.36\]0.23 TCchange0.78\[4.07,-2.17\]0.47final value−0.5\[0.41,-0.66\]0.63 TGchange0.68\[−0.36,0.59\]0.73final value1.27\[−0.47,1.85\]0.22 HDLchange0.16\[−3.43,3.90\]0.88final value−0.28\[−1.32,1.02\]0.79 LDLchange0.14\[−2.47,2.77\]0.891final value−3.03\[−2.81,-0.48\]0.009 HOMA-IRchange2.85\[−1.17,5.74\]0.104final value1.08\[−1.11,2.73\]0.329 HOMA-βchange−2.45\[−6.50,4.40\]0.247final value3.87\[−0.05,0.92\]0.061 HS-CRPchange−1.99\[−3.72,1.37\]0.185final value−0.76\[−4.7,3.28\]0.525 IMTchange0.71\[−17.94,20.08\]0.605

The characteristics of the studied populations varied with baseline values ranging from 42% to 70% for the proportion of males, 18 to 80 years for age. The length of follow-up ranged from 1/2 to 52 months.

Effect on body mass index and waist circumference {#Sec8}
-------------------------------------------------

Nine studies are received in BMI, comprising 338 patients of low GV and 353 patients of high GV, and baseline mean values range from 23 (kg/m^2^) to 26 (kg/m^2^). Reduction in BMI was observed in 4 of the 10 studies. The meta-analysis revealed that BMI levels were not significantly higher in HGVG than in LGVG (mean difference \[MD\] = 0.28 kg/m^2^ (95% confidence interval \[95% CI\] -0.1 to 0.67) with evidence of heterogeneity between studies (I^2^ = 32%; *P* = 0.16), and reduced BMI levels also did not reach statistical significance (MD = 0.01 kg/m^2^, 95% CI: = − 0.07 to 0.09; I^2^ = 23%; *P* = 0.28) (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Table 3Summary of results for CVD risk factorsCVD risk factorsPopulationNo.of studiesNo.of patientsTest of associationTest of heterogeneityH GVL GVMD95%Cl*P*-valueModel*P*-valueI^2^ BMIchangeoverall42182250.01\[−0.07,0.09\]0.82R0.2823%final valueoverall93533380.28\[−0.10,0.67\]0.15R0.1632% WCchangeoverall284871.35\[−1.13,3.83\]0.29R0.810%final valueoverall51651591.11\[−0.99,3.22\]0.30R0.490% TCchangeoverall7468488−0.12\[−0.26,0.01\]0.07R0.1833%final valueoverall16661639−0.03\[−0.06,0.00\]0.06R0.780% TGchangeoverall63173380.19\[0.07,0.30\]0.002R0.1736%final valueoverall168079390.02\[−0.07,0.11\]0.67R0.1528% HDLchangeoverall167598910.02\[−0.02,0.05\]0.36R0.1231%final valueoverall7451474−0.01\[−0.05,0.03\]0.70R0.2424% LDLchangeoverall16779911−0.01\[−0.10,0.07\]0.74R0.2121%final valueoverall7468483−0.05\[−0.13,0.02\]0.13R0.570% HOMA-IRchangeoverall42472560.18\[−0.00,0.37\]0.05R0.430%final valueoverall73863780.58\[0.26,0.91\]0.0004R0.470% HOMA-βchangeoverall31471448.44\[−4.53,21.4\]0.2R0.50%final valueoverall42392361.53\[−2.94,6.00\]0.5R0.950% HS-CRPchangeoverall42552710.33\[−0.09,0.76\]0.12R0.3312%final valueoverall4179178−0.24\[−0.73,0.25\]0.33R0.600% IMTchangeoverall32242260.28 (SMD)\[0.09,0.47\]0.003R0.480%

Five studies comprise 165 patients of high GV and 159 patients of low GV in WC. The meta-analysis revealed that waist circumference level was not associated with glucose variability level (MD = 1.11 cm, 95% CI: = −0.99 to 3.22), with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.49) and reduced WC levels also did not reach statistical significance (MD = 1.35, 95% CI: = − 1.13 to 3.83; I^2^ = 0%; *P* = 0.81) (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S2).

Effect on insulin secretion and insulin resistant {#Sec9}
-------------------------------------------------

Eight studies of HOMA-IR comprise 406 patients of high GV and 399 patients of low GV. Reduction in HOMA-IR was observed in 2 \[[@CR19], [@CR20]\] of the 8 studies. The meta-analysis revealed that HOMA-IR level was significantly lower in LGVG than in HGVG (MD = 0.58, 95% CI: = 0.26 to 0.91, *P* = 0.0004), with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.47), however, reduced HOMA-IR were not statistical significance (MD = 0.18, 95% CI: = − 0.00 to 0.37; I^2^ = 0%; *P* = 0.43) (Table [3](#Tab3){ref-type="table"}, Fig [2](#Fig2){ref-type="fig"}).Fig. 2Forest plots of the effect of glucose variability for CVD risk factors in type 2 diabetes patients, showing differences in outcomes of trials with LGVG and HGVG. (i) Effect of GV on HOMA-IR. (ii) Effect of GV on IMT. (iii) Effect of GV on TG. (CL: confidence interval. LGVG: low glucose variability group. HGVG: high glucose variability group. IMT: carotid intima-media thickness TG: triglyceride

Six studies of HOMA-β comprise 302 patients of high GV and 299 patients of low GV. One of five studies inβ-cell function was an increase after lower GV. The pooled weighted mean difference was 1.53 (95% CI = −2.94 to 6.00, *P* = 0.5), with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.95). And HOMA-β of the pooled mean change was 8.44 (95% CI = −4.53 to 21.4, *P* = 0.2), with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.5) (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S7). Whatever final levels and changes of HOMA-β both were no association with GV.

Effect on lipid metabolism {#Sec10}
--------------------------

The meta-analysis revealed that lipid metabolism level was not associated with glucose variability based on TC, TG, HDL and LDL levels. Eighteen studies about TC, it is that MD = −0.03 mmol/l, 95% CI: = −0.06 to 0.00, with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.78) (Table [3](#Tab3){ref-type="table"}). Twenty-two studies about TG, it is that MD = 0.02 mmol/l, 95% CI: = −0.07 to 0.11, with evidence of heterogeneity between studies (I^2^ = 28%; *P* = 0.15) (Table [3](#Tab3){ref-type="table"}, Fig [2](#Fig2){ref-type="fig"}). Eighteen studies about HDL, it is that MD = −0.01 mmol/l, 95% CI: = −0.05 to 0.03, with evidence of heterogeneity between studies (I^2^ = 24%; *P* = 0.24) (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S3). Twenty studies about LDL, it is that MD = −0.05 mmol/l, 95% CI: = −0.13 to 0.02, with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.57) (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S4).

However, we found that GV were associated with reduced TG (MD = 0.19 mmol/l; 95% CI: \[0.07, 0.3\]; I^2^ = 36%; *P* = 0.17), and a trend towards reduced others' levels which did not reach statistical significance: TC (MD = −0.12 mmol/l; 95% CI: \[−0.26, 0.01\]; I^2^ = 33%; *P* = 0.18), HDL (MD = 0.02 mmol/l; 95% CI: \[−0.02, 0.05\]; I^2^ = 31%; *P* = 0.12) and LDL (MD = −0.01 mmol/l; 95% CI: \[−0.10, 0.07\]; I^2^ = 21%; *P* = 0.21) (Table [3](#Tab3){ref-type="table"}).

Effect on inner metatarsal tubercle and high sensitivity C reactive protein {#Sec11}
---------------------------------------------------------------------------

Seven studies of Hs-CRP comprise 417 patients of high GV and 426 patients of low GV. The meta-analysis revealed that Hs-CRP level was not associated with glucose variability (MD = −0.24 ng/ml, 95% CI: = −0.73 to 0.25, *P* = 0.33), with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.6) and reduced WC levels also did not reach statistical significance (MD = 0.33 ng/ml, 95% CI: = − 0.09 to 0.76; I^2^ = 12%; *P* = 0.33) (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S6).

Three studies of IMT comprise 224 patients of high GV and 226 patients of low GV. The meta-analysis revealed that reduced IMT level was significantly lower in LGVG than in HGVG (SMD = 0.28 mm, 95% CI: = 0.09 to 0.47, *P* = 0.003), with evidence of heterogeneity between studies (I^2^ = 0%; *P* = 0.48) (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}).

Discussion {#Sec12}
==========

The meta-analysis focuses on how GV affect CVD risk factors among 2 diabetes patients, as L Nalysnyk reported that GV was a significant positive association with the development or progression of diabetic retinopathy, even cardiovascular events and mortality \[[@CR21]\]. This meta-analysis showed that glucose variability might affect IMT and insulin resistant. However, the effects of GV on BMI, WC, HOMA-β, lipid metabolism and Hs-CRP were not statistically significant. At the same time, Brohall G reported that impaired glucose tolerance showed a higher IMT \[[@CR22]\]. That explained that it might be association among GV, IMT and insulin resistant, in order to provide opportunities for novel treatments.

IMT has been shown a significant predictor of CVD patients \[[@CR23]\]. In this meta-analysis, minimizing GV is accompanied by a reduction of IMT with an estimated magnitude between 0.09 and 0.47 mm, which is consistent with an estimated 11% to 59% reduction in risk of myocardial infarction and a 13% to 70% reduction in risk of stroke \[[@CR24]\]. Meanwhile, some studies found that IMT was associated with Phosphoinositide 3-kinase (PI3K) \[[@CR25]\] and AMPK pathway \[[@CR26]\], suggesting GV possibly affect IMT through PI3K or AMPK pathway.

Verona Diabetes Complicated Study \[[@CR27]\] previously postulated that HOMA-IR was also an significant predictor of cardiovascular disease in type 2 diabetes. ApoE2/2 mice without insulin resistance, which had a single allele of the insulin receptor deleted, will not enhance the severity of atherosclerosis \[[@CR28]\]. It has long been known that the insulin resistance in type 2 diabetes is caused by decrease in receptor concentration and kinase activity, the concentration and phosphorylation of insulin receptor substrate-1/−2, PI3K activity, and glucose transporter translocation \[[@CR29]\]. Thus insulin resistant plays a significant role on mac-complications, especially atherosclerosis. Now that GV could affect insulin resistant, so the improvement of GV might have beneficial effects not only on glucose control but also on CVD in type 2 diabetes.

Evidence continues to point to PI3K, which is only common between insulin resistant and IMT, and AKT is activated downstream of PI3K. It is also consistent that people with impaired glucose tolerance show a higher IMT \[[@CR22]\]. As our knowledge, PI3K/Akt mediates recruitment of glucose transporter GLUT4 and also enhances glucose oxidation, and it can effect endothelial function and inhibit cell apoptosis of myocardial cells. So according to our meta-analysis, we speculated that the one pathogenesis of GV is probably to affect PI3K/AKT single pathway, then aggravated glucose tolerance and increased IMT levels, further leaded to CVD events.

Although no statistical significance between lipid metabolism and GV in this meta-analysis, change of TG was effected by GV. Because the limited study number, short trial duration, and inconsistent of GV index may contribute non-statistical. As my knowledge, TG can be possibly maintained to prevent insulin resistance. Hypertrophy of adipocytes on overloading TG significantly increases inflammatory status, especially tumour necrosis factor-α (TNF-α) \[[@CR30]\]. The reason is possibly that TG is the main maker to affect insulin resistance in the lipid metabolism. So the key question is what are the mechanisms on the reduced TG in type 2 diabetes? Inflammatory factor, especially TNF-α, may be effected by GV, because of limitation of studies, we failed to explore the association between them. More theoretical work is needed to better understand the mechanism of GV, how it may be related to outcomes of interest and how to effectively change TG and inflammatory factor.

This meta-analysis has some limitations that should be considered. First, some of the studies had small sample size, especially meta-analysis of IMT levels. So caution is needed in the interpretation of the result from the meta-analysis, since the meta-analysis may have been underpowered. Second, in this meta-analysis, some studies were heterogeneous in terms of demographic characteristics and clinical features. This heterogeneity, as well as confounding factors such as different treatment, different measuring methods and limited clinical information, could affect the results. Nevertheless, the meta-analysis also has advantage. A strength of this study is to include studies published in English and Chinese languages, and no publication restrictions, all available data were included, thereby increasing the power of the study.

Conclusion {#Sec13}
==========

The healthy people maintain a balance in glucose uptake and production, and the GV could break the balance. And this meta-analysis show that minimizing GV is effective in improving the insulin resistance and IMT that are associated directly with cardiovascular disease. In other words, this analysis indicates that HOMA-IR and IMT possibly play an important role in glucose variability pathogenesis. Further studies are needed to determine how GV directly contribute to the pathogenesis of CVD in detail.
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